Central Events on the First Night of an Oral Appliance
A 58-year-old man with treated hypertension and paroxysmal atrial fibrillation, BMI 28, was diagnosed with moderate OSA (AHI 18, predominantly obstructive). He declined CPAP and was fitted with a custom adjustable MAD, advanced over six weeks to a comfortable maximum. He reports better sleep but still wakes unrefreshed. A home sleep apnea test on the appliance shows AHI 11, with 40% of events flagged as central or 'mixed,' and a Cheyne-Stokes pattern noted by the scorer. He has no known heart failure. His medications include metoprolol and a nightly opioid for chronic back pain.
1. How do you interpret the central events on the treatment study, and what must be ruled out before concluding the appliance 'failed'?
Read the worked answer
Central and mixed events appearing on a treatment study in a patient with predominantly obstructive disease should raise several possibilities. First, treatment-emergent central sleep apnea: opening the airway can unmask or precipitate central events in susceptible patients, and this is a recognized phenomenon with PAP and has been described with oral appliances. Second, the scorer's Cheyne-Stokes annotation on a home study is a pattern impression that warrants confirmation; home devices have limited channels and can misclassify. Third, his opioid use is a well-known cause of central and ataxic breathing, and his metoprolol and atrial fibrillation history add cardiac context. Fourth, the home study may have underestimated events because of limited channels and no EEG.
The correct move is not to declare failure but to escalate the diagnostic quality: refer for an in-lab polysomnogram on the appliance with full EEG, effort belts, and end-tidal CO2 or transcutaneous CO2, and have the sleep physician review the raw data. Also review the opioid regimen with the prescriber. Only after a properly scored in-lab study can you determine whether the appliance is producing residual obstructive events, treatment-emergent central events, or opioid-related central apnea.
2. What does the atrial fibrillation history add to your risk assessment and coordination?
Read the worked answer
Untreated or undertreated OSA is associated with increased atrial fibrillation burden and recurrence after cardioversion or ablation. His residual AHI of 11 with central events is not reassuring, and his unrefreshing sleep suggests the therapy is not yet effective. The dental sleep team should communicate with his cardiologist or electrophysiologist that OSA therapy is being optimized and that control is not yet demonstrated, so that any rhythm management decisions are made with that information.
This also reinforces that the endpoint is not 'the patient is wearing the appliance' but objective control. If the in-lab study shows residual obstructive disease, further advancement or combination therapy is indicated. If it shows central apnea, the appliance is not the right sole therapy and the physician should consider other modalities. Document the coordination and the shared plan.
3. If the in-lab study confirms treatment-emergent central apnea, what is your recommendation regarding the appliance?
Read the worked answer
Treatment-emergent central apnea on an oral appliance is a signal that the appliance alone is not achieving safe control, even if obstructive events are reduced. The recommendation should be developed jointly with the sleep physician. Reasonable options include continuing the appliance while adding or transitioning to PAP with adaptive servo-ventilation or another modality appropriate to the central pattern, or discontinuing the appliance if it is not contributing. The opioid should be addressed with the prescriber as a potentially reversible contributor. The dental team's role is to maintain the appliance if it is retained as part of combination therapy, monitor dental status, and avoid implying that further advancement will fix a central pattern. Document that the appliance was not deemed definitive therapy and that the physician assumed management of the central apnea.